[Regulation of XW630 on TGF-beta 1 and collagen I gene expression in osteoblasts].
The purpose of this part of study was to investigate the mechanism of a new anti-osteoporotic drug, XW630 on promoting osteogenic activity. Total RNA were isolated from osteoblasts of the mice after the reaction with XW630 in 24 and 72 hours, that were hybridized with the extracted and digoxigenin-labeled TGF-beta 1 and the collagen I cDNA probes. XW630 significantly promoted TGF-beta 1 and collagen I gene expression in osteoblasts, and this drug was superior than other two kinds of estrogen in promoting osteogenic activity (P < 0.05). XW630 promote osteogenic activity of osteoblasts, probably by enhancing the mRNA expression of TGF-beta 1 and collagen I.